BOSENTAN (bosentan) by Teva is . Approved for pulmonary arterial hypertension (pah) (who group 1): in adults to improve exercise ability, to decrease clinical worsening, hypertension. First approved in 2019.
Drug data last refreshed 1w ago
. Bosentan has a slightly higher affinity for ET A receptors than for ET B receptors. The clinical impact of dual endothelin blockage is unknown. Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET A and ET B receptors in the endothelium and vascular smooth…
Worked on BOSENTAN at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan